CMX001 in Post-transplant Patients With BK Virus Viruria
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
This was a randomized, double-blind, multiple-dose placebo-controlled study of oral
brincidofovir (BCV) in hematopoietic stem cell transplant and renal transplant recipients
with BK virus viruria.